Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:06 PM ET Form 4
Insider Selling JFrog Ltd FROG

JFrog CEO Ben Haim Shlomi Sells $1.45M of Stock

Ben Haim Shlomi, CEO, sold 14,924 shares of JFrog Ltd at $90.52 to $97.92 a share (average $97.43) in 6 transactions, worth $1.45M in total on Nov 6, 2026. Shares held after the trade: 4,419,305 (-0.2%).

Value
$1.45M
Shares
14,924
Average price
$97.43
Role
CEO
Holding change
-0.2%
Trade date
Nov 6, 2026
4:06 PM ET 8-K
Capital Raise FrontView REIT, Inc. FVR

FrontView REIT Capital Raise of $30M

FrontView REIT, Inc. issued 300,000 shares of Series A Convertible Preferred Stock at $100.00 per share, raising gross proceeds of approximately $30.0 million. The private placement was made to a group of institutional investors including Maewyn FVR II LP and Petrus Special Opportunities Fund under a previously established investment agreement.

Value
$30M
Counterparty
Maewyn FVR II LP, Rebound Investment, LP and Petrus Special Opportunities Fund, L.P.
4:06 PM ET 8-K
Financial Results Capricor Therapeutics, Inc. CAPR

Capricor Therapeutics Financial Results

Capricor Therapeutics reported Q3 2026 financial results and provided a regulatory update on its BLA for Deramiocel in Duchenne muscular dystrophy, which has a PDUFA date of November 22, 2026. The company ended the quarter with approximately $199 million in cash and marketable securities. Management highlighted clinical data showing a 76% slowing of upper limb decline in patients who switched to Deramiocel during the HOPE-3 open-label extension.

Term
Q3 2026

“This quarter, we took important steps forward on both our regulatory filing and our launch readiness, submitting two-year HOPE-3 OLE data in a major amendment to our BLA while advancing our manufacturing and commercial preparations. In the OLE phase, patients who switched from placebo to Deramiocel saw their upper limb decline slow by 76% compared with their year on placebo, and this past weekend our HOPE-3 cardiac results received the AHA Outstanding Research Award in Pediatric Cardiology.”

Linda Marbán, Ph.D., Capricor’s Chief Executive Officer

“As Duchenne progresses, boys and young men lose the use of their arms and hands, and with it their independence, which is what Deramiocel is designed to slow. We appreciate the FDA’s engagement throughout this review and are encouraged by the Agency’s current focus on rare disease, including its recently launched Rare Disease Framework Initiative. As we approach our PDUFA date, we remain confident in the strength of our data. With our San Diego facility operational, we are prepared to move quickly to bring Deramiocel to patients, if approved.”

Linda Marbán, Ph.D., Capricor’s Chief Executive Officer
4:06 PM ET 8-K
Financial Results Braveheart Bio, Inc. BRVE

Braveheart Bio Financial Results

Braveheart Bio reported third quarter 2026 financial results, ending the period with $503.5 million in cash and investments, providing a runway into 2029. The company highlighted 52-week clinical data for BHB-1893 in obstructive HCM and outlined an updated Phase 3 development strategy designed to simplify dosing and minimize titration.

Term
Q3 2026

“BHB-1893 continues to show a consistent, potentially differentiated profile across multiple clinical studies and our mechanistic work. The 52-week data presented at AHA showed rapid, deep responses that continued to improve over time, including meaningful improvements in pVO2 and KCCQ-CSS, and evidence supporting a highly simplified dosing regimen.”

Travis Murdoch, M.D., President and Chief Executive Officer
4:06 PM ET Form 4
Insider Selling Bill Holdings, Inc. BILL

Bill Holdings CEO Rene A. Lacerte Sells $3.19M of Stock

Rene A. Lacerte, CEO, sold 60,000 shares of Bill Holdings, Inc. at $53.00 to $53.19 a share (average $53.18) in 3 transactions, worth $3.19M in total between Nov 6, 2026 and Nov 9, 2026. Shares held after the trade: 0 (-100.0%).

Value
$3.19M
Shares
60,000
Average price
$53.18
Role
CEO
Holding change
-100.0%
Trade date
Nov 6, 2026 to Nov 9, 2026
4:06 PM ET Form 4
Insider Selling Telos Corp TLS

Telos Controller, Chief Acct Officer Donald Joseph Terreri Sells $69.7K of Stock

Donald Joseph Terreri, Controller, Chief Acct Officer, sold 9,400 shares of Telos Corp at $7.42 a share, worth $69.7K in total on Nov 10, 2026. Shares held after the trade: 24,083 (-28.1%).

Value
$69.7K
Shares
9,400
Price
$7.42
Role
Controller, Chief Acct Officer
Holding change
-28.1%
Trade date
Nov 10, 2026
4:05 PM ET 8-K
Financial Results Grove Collaborative Holdings, Inc. GROV

Grove Collaborative Holdings Financial Results

Grove Collaborative reported its third quarter 2026 financial results, achieving its first quarter of positive net income since becoming a public company. While total net revenue declined 15.8% year-over-year to $36.8 million, it grew 0.7% sequentially, marking the second consecutive quarter of sequential growth. The company also narrowed its full-year 2026 revenue guidance to a range of $144 million to $146 million.

Term
Q3 2026

“Third quarter results reflect the operating discipline we have built over the past several quarters. Net Revenue grew sequentially for the second consecutive quarter to $36.8 million. We also delivered positive Adjusted EBITDA for the fourth consecutive quarter, and delivered positive Adjusted EBITDA and net income in the same quarter for the first time since becoming a publicly-traded company.”

Jeff Yurcisin, Chief Executive Officer of Grove Collaborative
4:05 PM ET 10-Q
Financial Results Orchestra BioMed Holdings, Inc. OBIO

Orchestra BioMed Holdings Q3 2026 Results: Net Loss of $18.8M, Loss Narrows

Orchestra BioMed reported a significant decrease in total revenue to $0.29 million for the nine months ended September 30, 2026, compared to $2.57 million in the prior year, primarily due to the absence of partnership revenue. The company's total stockholders' equity declined from $53.6 million to $7.8 million as the accumulated deficit reached $425.8 million.

Key figure
Net loss $18.8M
4:05 PM ET 10-Q
Financial Results Opus Genetics, Inc. IRD

Opus Genetics Q3 2026 Results: Net Loss of $46.5M, Loss Widens

Opus Genetics reported a significant increase in net loss to $120.1 million for the nine months ended September 30, 2026, primarily driven by a $72.8 million fair value change in financial instruments. Despite the loss, the company strengthened its balance sheet through $82.9 million in financing activities, including a note purchase agreement and Series B preferred stock issuance, ending the period with $89.0 million in cash and cash equivalents.

Key figure
Net loss $46.5M
4:05 PM ET 8-K
Business Update Factorial Energy Inc. FAC

Factorial Energy Business Update

Factorial Energy reported its third quarter 2026 results, highlighting the generation of its first commercial revenue ahead of its 2027 target. The company also achieved a 450 Wh/kg energy density target for its aerospace cells and noted successful real-world range testing with Mercedes-Benz and Stellantis vehicles.

4:05 PM ET 10-Q
Financial Results Parkervision Inc PRKR

Parkervision Q3 2026 Results: Turns Profitable, Net Income $903K

For the nine months ended September 30, 2026, ParkerVision reported a net loss of $0.5 million and a working capital deficit of $0.8 million. The company expressed substantial doubt about its ability to continue as a going concern, noting that its liquidity is dependent on successful patent licensing, litigation settlements, and potential additional financing.

Key figure
Net income $903K
4:05 PM ET 8-K
Financial Results Tela Bio, Inc. TELA

Tela Bio Financial Results

TELA Bio reported Q3 2026 revenue of $19.0 million, an 8% decrease year-over-year primarily due to lower OviTex PRS volumes. The company implemented a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million and extend its cash runway into 2028. During the quarter, the company also regained Nasdaq compliance and received 510(k) clearance for its Liora Monofilament Scaffold.

Term
Q3 2026

“My first quarter as CEO was focused on putting a plan in place to return TELA Bio to growth. I joined because I believe OviTex is best-in-class technology and that we are well positioned to win in an evolving soft tissue repair and reconstruction market.”

Heather Getz, Chief Executive Officer of TELA Bio

“Our cost reduction initiative allows us to thoughtfully reallocate resources, supports a return to topline growth, and extends our cash runway. In the third quarter alone, we reduced our adjusted EBITDA loss by 55% versus the second quarter of 2026 while delivering sequential revenue growth in the US hernia market and continued year-over-year growth in Europe.”

Heather Getz, Chief Executive Officer of TELA Bio
4:05 PM ET 8-K
Stock Buyback Castellum, Inc. CTM

Castellum Announces $6M Stock Buyback

Castellum's Board of Directors has authorized a share repurchase program to buy back up to $6.0 million of its common stock over a 12-month period starting November 12, 2026. The company intends to fund the repurchases using its available cash, which stood at $15.7 million as of September 30, 2026. Management stated the buyback reflects confidence in the company's long-term growth strategy and a belief that the current share price is undervalued.

Value
$6M
Term
12 months
4:05 PM ET Form 4
Insider Selling uniQure N.V. QURE

uniQure Insider David D. Meek Sells $193K of Stock

David D. Meek sold 9,080 shares of uniQure N.V. at $21.25 a share, worth $193K in total on Nov 6, 2026. Shares held after the trade: 30,667 (-22.8%).

Value
$193K
Shares
9,080
Price
$21.25
Holding change
-22.8%
Trade date
Nov 6, 2026
4:04 PM ET 10-Q
Financial Results Grayscale Ethereum Classic Trust (ETC) ETCG

Grayscale Ethereum Classic Trust Q3 2026 Results: Net Income $19.6M, Up 18.2% YoY

Grayscale Ethereum Classic Trust reported a net asset value of $94.9 million as of September 30, 2026, a decrease from $126.0 million at year-end 2025. The Trust experienced a net loss from operations of $31.1 million for the nine months ended September 30, 2026, primarily driven by $29.5 million in unrealized depreciation of its Ethereum Classic holdings.

Key figure
Net income $19.6M · +18.2% YoY
4:04 PM ET 8-K
Financial Results Achieve Life Sciences, Inc. QUIT

Achieve Life Sciences Financial Results

Achieve Life Sciences (rebranded as AchieveRx) reported third quarter 2026 financial results and provided a regulatory update on its smoking cessation drug, cytisinicline. The company remains on track to resubmit its New Drug Application (NDA) to the FDA in Q4 2026 and ended the period with $201.5 million in cash and equivalents.

Term
Q3 2026

“Becoming AchieveRx, The Quit Company, reflects our shift from a clinical-stage company to one preparing to launch what could be the first new FDA-approved prescription medicine in 20 years to help people who smoke quit.”

Andrew D. Goldberg, MD, Chief Executive Officer

“Our 52-week ORCA-OL results add to the growing body of evidence supporting cytisinicline as a potential treatment option for people looking to quit smoking. With an experienced launch team and our NDA resubmission on track for later this year, we are well positioned to bring cytisinicline to people who want to quit, if it is approved.”

Andrew D. Goldberg, MD, Chief Executive Officer
4:04 PM ET Form 4
Insider Selling Otis Worldwide Corp OTIS

Otis Worldwide President, Otis EMEA Thibault Pierre Marie Lefebure Sells $71.1K of Stock

Thibault Pierre Marie Lefebure, President, Otis EMEA, sold 900 shares of Otis Worldwide Corp at $78.95 a share, worth $71.1K in total on Nov 9, 2026. Shares held after the trade: 3,108 (-22.5%).

Value
$71.1K
Shares
900
Price
$78.95
Role
President, Otis EMEA
Holding change
-22.5%
Trade date
Nov 9, 2026
4:04 PM ET Form 4
Insider Selling Generac Holdings Inc. GNRC

Generac Holdings President Generac Home Norman P. Taffe Sells $19K of Stock

Norman P. Taffe, President Generac Home, sold 100 shares of Generac Holdings Inc. at $190.00 a share, worth $19K in total on Nov 9, 2026. Shares held after the trade: 10,676 (-0.9%).

Value
$19K
Shares
100
Price
$190.00
Role
President Generac Home
Holding change
-0.9%
Trade date
Nov 9, 2026
4:04 PM ET 8-K
Financial Results Ambow Education Holding Ltd. AMBO

Ambow Education Holding Financial Results

Ambow Education reported Q3 2026 financial results with net revenues increasing 21.4% year-over-year to $1.7 million, driven by growth in both educational programs and HybriU licensing. The company reduced its net cash used in operating activities by half during the first nine months of the year while increasing investments in R&D and marketing ahead of CES 2027.

Term
Q3 2026
4:04 PM ET 10-Q
Financial Results Public Policy Holding Company, Inc. PPHC ▶ Call

Public Policy Holding Company Q3 2026 Results: Turns Profitable, Net Income $236K

Public Policy Holding Company reported revenue of $55.2 million for the third quarter of 2026, up from $48.8 million in the prior year period. Despite a loss from operations of $8.3 million, the company achieved a small net income of $0.2 million for the quarter, aided by a $9.8 million gain on a bargain purchase. Total assets grew to $259.8 million as of September 30, 2026, compared to $202.6 million at year-end 2025.

Key figure
Net income $236K
4:04 PM ET 8-K
Financial Results Grocery Outlet Holding Corp. GO

Grocery Outlet Holding Financial Results

Grocery Outlet reported Q3 2026 financial results with net sales increasing 0.9% to $1.18 billion and a return to positive comparable store sales growth of 0.5%. Net income rose to $13.3 million, or $0.13 per diluted share, despite a 40 basis point decline in gross margin driven by product promotions and higher transportation costs.

Term
Q3 2026

“In the third quarter we returned to positive comparable store sales, driven by continued improvements to the execution of our opportunistic product offering. Traffic accelerated and basket trends again improved sequentially as we enhanced our value proposition.”

Jason Potter, President and CEO
4:04 PM ET 8-K
Financial Results Parkervision Inc PRKR

Parkervision Financial Results

ParkerVision reported a net loss of $0.5 million for the first nine months of 2026, a significant improvement from the $7.4 million loss in the prior year period. The results were driven by a 46% reduction in operating expenses and a $3.4 million gain from the fair value adjustment of contingent payment obligations. Management also provided updates on ongoing patent litigation against Qualcomm, MediaTek, and Realtek, as well as a FOIA complaint against the National Archives.

Term
9 months ended September 30, 2026

“While we believe bifurcation of our Qualcomm case is inefficient, the appellate court's decision does not impact the merits of our case, and we are eager to pursue a jury trial on our transmitter claims as expeditiously as possible.”

Jeffrey Parker, CEO of ParkerVision

“We are looking forward to a response from the National Archives given that, to date, nearly a year since responsive documents have been identified, we have still not received any of the identified responsive documents to our request.”

Jeffrey Parker, CEO of ParkerVision
4:04 PM ET 8-K
Financial Results Bionano Genomics, Inc. BNGO

Bionano Genomics Financial Results

Bionano Genomics reported Q3 2026 revenue of $8.3 million, a 12% increase year-over-year, driven by a 24% rise in consumables revenue. The company reiterated its full-year 2026 revenue guidance of $31 million to $33 million and highlighted progress in the clinical adoption of its optical genome mapping (OGM) technology.

Term
Q3 2026

“Our third quarter results reflect the momentum building across our business and the broader genomics community, further accelerating the adoption of optical genome mapping (OGM) in clinical and commercial settings.”

Al Luderer, Ph.D., chairman and interim chief executive officer

“Coverage and regulatory progress this quarter helped build a clearer reimbursement pathway for OGM-based testing, which we expect to support broader clinical adoption over time.”

Al Luderer, Ph.D., chairman and interim chief executive officer
4:03 PM ET 8-K
Financial Results Worksport Ltd WKSP

Worksport Financial Results

Worksport Ltd. reported record Q3 2026 net sales of $7.2 million, a 44.2% increase year-over-year, driven by strong performance of its NEXUS product line. The company's net loss narrowed by 27% to $3.6 million as revenue growth significantly outpaced the increase in operating expenses. Management highlighted a 95% reduction in operating cash use since Q1 2026 as the company moves toward a just-in-time production model.

Term
Q3 2026
4:03 PM ET Form 4
Insider Buying Eastman Chemical Co EMN

Eastman Chemical SVP, Regions & Chf SupChn Ofcr Julie A. McAlindon Buys $160K of Stock

Julie A. McAlindon, SVP, Regions & Chf SupChn Ofcr, bought 2,451 shares of Eastman Chemical Co at $65.28 a share, worth $160K in total on Nov 6, 2026. Shares held after the trade: 20,650 (+13.5%).

Value
$160K
Shares
2,451
Price
$65.28
Role
SVP, Regions & Chf SupChn Ofcr
Holding change
+13.5%
Trade date
Nov 6, 2026
4:03 PM ET 8-K
Executive Compensation Blue Bird Corp BLBD

Blue Bird Executive Compensation

Blue Bird Corporation's Compensation Committee approved base salary increases and performance-based bonus payouts for its top executive officers, including CEO John Wyskiel and CFO Razvan Radulescu. The committee also increased the long-term equity incentive (LTIP) targets for the CEO and CFO and awarded additional performance multipliers for fiscal 2026 management incentive program (MIP) payments.

4:03 PM ET 10-Q
Financial Results Grayscale Bitcoin Cash Trust (BCH) BCHG

Grayscale Bitcoin Cash Trust Q1 2026 Results: Net Income $39.3M, Up 161.7% YoY

For the three months ended September 30, 2026, Grayscale Bitcoin Cash Trust reported a net increase in net assets resulting from operations of $39.3 million, driven by $40.2 million in unrealized appreciation of BCH. The Trust's net assets grew from $76.6 million at the start of the period to $115.9 million, while the Principal Market NAV per Share increased from $1.62 to $2.46.

Key figure
Net income $39.3M · +161.7% YoY
4:03 PM ET 8-K
Investor Presentation Unusual Machines, Inc. UMAC

Unusual Machines Investor Presentation

Unusual Machines uploaded a new investor presentation to its website and announced that CEO Allan Evans will present at the Baird 2026 Global Industrial Conference on November 11, 2026. The presentation highlights the company's NDAA-compliant drone component manufacturing, its pending acquisition of Upgrade Energy, and a strong balance sheet with over $162 million in cash and no debt.

4:03 PM ET 10-K
Financial Results Sally Beauty Holdings, Inc. SBH ▶ Call

Sally Beauty Holdings FY 2026 Results: Net Income $200M, Up 2.1% YoY

Sally Beauty Holdings reported fiscal 2026 consolidated net sales of $3,734.6 million, a 0.9% increase driven by favorable foreign currency and a 0.5% increase in comparable sales. While consolidated net earnings grew 2.1% to $200.1 million, operating earnings saw a slight 0.4% decrease due to the absence of a prior-year gain on a headquarters sale.

Key figure
Net income $200M · +2.1% YoY
4:03 PM ET Form 4
Insider Selling AtriCure, Inc. ATRC

AtriCure Insider B. Kristine Johnson Sells $143K of Stock

B. Kristine Johnson sold 2,452 shares of AtriCure, Inc. at $58.48 a share, worth $143K in total on Nov 6, 2026. Shares held after the trade: 53,502 (-4.4%).

Value
$143K
Shares
2,452
Price
$58.48
Holding change
-4.4%
Trade date
Nov 6, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.